- 1 Article Title: Lack of evidence for interactions between APOE and Klotho genotypes on
- 2 cognitive, dementia and brain imaging metrics in UK Biobank.
- 3 Authors: Rachana Tank MSc¹, Joey Ward BSc¹, Daniel J. Smith MD¹, Kristin E. Flegal²
- 4 PhD, Donald M. Lyall PhD¹.
- 5
- ⁶ ¹Institute of Health & Wellbeing, University of Glasgow, Scotland, UK.
- ⁷²Institute of Neurosciences and Psychology, University of Glasgow, Glasgow, Scotland, UK.
- 8

9 **Corresponding author**

- 10 Dr. Donald M. Lyall
- 11 1 Lilybank Gardens
- 12 Institute of Health and Wellbeing
- 13 University of Glasgow
- 14 G12 8RZ, Glasgow, UK.
- 15 Email: <u>Donald.Lyall@Glasgow.ac.uk</u>
- 16 Tel: +44 (0) 141 330 8547
- 17 Fax: +44 (0) 141 330 1874
- 18 **Search terms:** *Cognitive; dementia; brain; APOE; Klotho.*
- 19 Acknowledgements: This research has been conducted using the UK Biobank resource;
- 20 we are grateful to UK Biobank participants. Thanks to Dr. Breda Cullen for devising
- 21 exclusion criteria and Dr. Michael A. Belloy for helpful comments on an earlier draft. This
- 22 project was completed using UK Biobank application 17689 (PI: DML).
- 23 Title character count: 132
- 24 **Text word count**: 1295
- 25 Abstract word count: 245
- 26 Supplementary Tables: 1
- 27 References: 17

28 Abstract

<u>Importance</u>: Recent research has suggested that genetic variation in the *Klotho* (KL) locus
 may modify the association between apolipoprotein e (*APOE*) e4 genotype and cognitive
 impairment.

32 <u>Objective</u>: Large-scale testing for associations and interactions between *KL* and *APOE* 33 genotypes vs. risk of dementia (n=1,570 cases), cognitive abilities (n=174,513) and brain 34 structure (n = 13,158) in older (60+ years) participants.

35 <u>Design, setting and participants</u>: Cross-sectional and prospective data (UK Biobank).

Main outcomes and measures: *KL* status was indexed with heterozygosity of the rs9536314 polymorphism (vs. not), in unrelated people with vs. without *APOE* e4 genotype, using regression and interaction tests. We assessed non-demented cognitive scores (processing speed; reasoning; memory; executive function), multiple structural brain imaging, and clinical dementia outcomes. All tests were corrected for age, sex, assessment centre, eight principal components for population stratification, genotypic array, smoking history, deprivation, and self-reported medication history.

<u>Results</u>: *APOE* e4 presence (vs. not) was associated with increased risk of dementia, worse
cognitive abilities and brain structure differences. *KL* heterozygosity was associated with
less frontal lobe grey matter. There were no significant *APOE/KL* interactions for cognitive,
dementia or brain imaging measures (all P>0.05).

47 <u>Conclusions and relevance</u>: We found no evidence of *APOE/KL* interactions on cognitive, 48 dementia or brain imaging outcomes. This could be due to some degree of cognitive test 49 imprecision, generally preserved participant health potentially due to relatively young age, 50 type-1 error in prior studies, or indicative of a significant age-dependent KL effect only in the 51 context of marked AD pathology.

53 Key points

- **Question**: *Klotho* genotype has been previously shown to 'offset' a substantial amount of
- 55 the APOE e4/cognitive impairment association. Is this modification effect apparent in
- 56 large-scale independent data, in terms of non-demented cognitive abilities, brain
- 57 structure and dementia prevalence?
- **Findings**: In aged 60 years and above participants from UK Biobank, we found
- 59 significant associations of APOE and Klotho genotypes on cognitive, structural brain and
- 60 dementia outcomes, but no significant interactions.
- **Meaning**: This could reflect somewhat healthy participants, prior type 1 error or
- 62 cognitive/dementia ascertainment imprecision, and/or that Klotho genotypic effects are
- 63 age and neuropathology dependent.

64 Introduction

65 Preserving cognitive abilities such as memory is a common concern into older age, and in 66 the absence of reliable treatments, the public health priority is prevention and delay of 67 cognitive impairment¹, including understanding effect modifiers. APOE e4 is a known risk 68 factor for AD and cognitive decline¹. Genetic variation in the KL locus has been associated 69 with ageing-related phenotypes including insulin resistance and brain function². A recent 70 study of AD cohorts, longitudinal conversion and amyloid-beta samples showed a 71 statistically significant 'modification' effect where the deleterious effects conferred by APOE 72 e4 were offset by heterozygosity based on two KL polymorphisms in strong linkage 73 disequilibrium: F352V (rs9536314) and C370S (rs9527025), possibly due to correlations with increased serum Klotho³. UK Biobank is a relatively large general population cohort⁴ where 74 we have previously shown deleterious effects of APOE e4 on cognitive⁵, structural brain 75 imaging⁶ and AD/dementia phenotypes⁷. This brief report tested the hypothesis that based 76 77 on recent research, genetic KL variation would interact with APOE e4 genotype in relevant 78 cognitive, brain and dementia phenotypes.

79

80 Methodology

81 Study design and participants

UK Biobank is a prospective cohort study including 502,628 participants who attended one of 22 baseline assessment centres from 2006 to 2010, aged 40-70 years⁸. In 2014, MRI scanning of a sub-group of 100,000 participants began, and this is ongoing. This analysis was conducted under generic approval from the NHS National Research Ethics Service (approval letter dated 17th June 2011, ref 11/NW/0382). Written informed consent was obtained from all participants in the study.

88 Dementia outcomes

Dementia/AD outcomes were generated using self-report, hospital admission and death record data, with data utilising International Classification of Diseases version 10 (ICD-10 codes). Individuals were designated as cases ("all-cause dementia" or "Alzheimer disease") if they had indicated either in self-report or hospital/death records – derived by UK Biobank^{7,9}. Those coded as missing were designated as controls (i.e. did not self-report dementia, and diagnoses not present in hospital/death records).

95

96 Imaging data

97 The release of brain MRI data as of July 2020 was used (i.e. approximately 40k). All imaging data used here was processed and quality checked by UK Biobank¹⁰. We selected imaging 98 99 phenotypes a priori shown to be associated with worse cognitive ability and decline total 100 white and grey volumes adjusted for skull size (WM/GM respectively); loa WM 101 hyperintensity volume (WMH); overall hippocampal volume; general factors of fractional anisotropy (FA) and mean diffusivity (MD), and frontal lobe GM (gFrontal)¹¹ based on 102 103 principal components analysis (PCA). Total WM hyperintensity volumes were calculated 104 based on T1 and T2 fluid-attenuated inversion recovery (FLAIR), derived by UK Biobank.

105

106 Cognitive data

Five tests were completed at baseline (2006-2010), of which we examine three here which have shown sufficient intra-participant reliabilities: Pairs-matching 6-pair (memory), verbalnumeric reasoning and log reaction time (processing speed)¹². We also examined four cognitive tests administered from 2014 onwards. These were: Trail making test a+b (processing speed/executive function) and Digit symbol substitution (executive function) assessed via online follow-up, plus Matrix pattern completion (nonverbal reasoning) and Tower rearranging (executive function) at MRI¹¹.

114

115 Genetic data

116 UK Biobank genotyping was conducted by Affymetrix using a bespoke BiLEVE Axiom array 117 for ~50,000 participants and the remaining ~450,000 on the Affymetrix UK Biobank Axiom 118 array. All genetic data were quality controlled by UK Biobank as described by the protocol 119 paper⁴.). *APOE* e4 'risk' genotype presence (vs. non-e4) was genotyped based on rs7412 120 and rs429358. KL was indexed using rs9536314 where G/T is considered protective (vs. 121 G/G; T/T) and synonymous with KL-VS diplotype heterozygosity¹³.

122

123 Covariates

Participants self-reported their smoking history: current, past or never, medication use for dyslipidaemia, hormone replacement therapy, blood pressure, oral contraceptive or insulin. We excluded participants for whom these data were missing (<5%). Townsend deprivation indices were derived from postcode of residence.

128

129 Statistical analysis

130 PLINK v1.90 was used for genetic quality controlling and Stata V.14 was used for statistical 131 analyses. We removed participants who reported neurological conditions as described previously¹². We statistically controlled for: age, sex, Townsend, ever-smoking, genotypic 132 133 array, baseline/MRI assessment centre, 8 principal components, array, and medication 134 (concurrent to the phenotype under study; dementia outcomes used baseline values). We 135 focussed on participants aged ≥60 years at baseline³. We excluded participants with non-136 white British ancestry, self-report vs. genetic sex mismatch, putative sex chromosomal 137 aneuploidy, excess heterozygosity, and missingness rate >0.1. We accounted for 138 relatedness between participants by removing one random participant in cases where two 139 individuals were 1st cousins or closer. We have previously reported power calculations 140 indicative of >95% confidence to find 'true' effect sizes at Cohen's D = 0.1 (i.e. small) with 141 regard to APOE genotype and outcomes in UK Biobank⁶.

142 **Results**

143 Descriptives

After exclusions there were baseline N=174,513 (mean age 64.1, SD=2.85) participants; imaging n=13,158 (72.24 years; SD 3.31). For rs9536314 there were 47,593 heterozygotes (G/T; 27%), and N=46,270 (26.63%) possessed an *APOE* e4 allele. There were n=1,570 dementia cases (0.9%) of which n=634 were AD (0.4%).

148

149 <u>Outcomes</u>

150 Supplementary Table 1 shows associations between APOE e4 genotype and multiple worse 151 outcomes: dementia (odds ratio[OR]=3.27 for e4 vs. not), AD (OR=5.06), log Tower 152 rearranging score (beta = -0.07 SDs for e4 vs. not), Matrix Reasoning (-0.11 SDs), frontal 153 lobe GM (-0.05), hippocampal volume (-0.10), overall GM (-0.06), log TMT total time (0.037) 154 and Digit symbol (-0.075; lowest P-value = 0.038). KL heterozygosity (vs. not) was 155 associated with gFrontal only (-0.041 SDs; P=0.043). There were no statistically significant 156 APOE/KL interactions. As sensitivity analyses all models were re-run: unadjusted then 157 covariates added incrementally; excluding people with concurrent neurological conditions¹²; 158 and using the full sample (aged <60). These made no difference to the results.

159

160 Discussion

A recent study by Belloy et al.³ reported a protective modifying effect of KL heterozygosity 161 162 on APOE e4 genotype's conferred risk on cognitive impairment and dementia, in a collation 163 of longitudinal, AD and amyloid-beta cohorts totalling N=24,743. Using unrelated UK 164 Biobank data we tested whether a similar effect could be seen in multiple outcomes: AD/all-165 cause dementia vs. not, and non-demented cognitive and structural brain MRI phenotypes 166 known to underlie cognitive decline. Participants were ≥60 years as per Belloy et al. We 167 identified individual APOE and KL genotype/outcome associations but no interactions, against our hypothesis. There could be an underestimation of true effect due to cognitive test 168 imprecision¹² or generally preserved participant health¹¹. No interaction here vs. Belloy et al. 169

170 could reflect the use of different phenotypes: the original study investigated AD case vs. 171 control status, conversion to impairment and amyloid-beta while this study investigated AD 172 status and non-demented cognitive/brain structure values. UK Biobank derived dementia 173 status largely from ICD codes whereas Belloy et al. used clinical and/or pathological 174 ascertainment. This could suggest that the age-dependent changes in KL expression, and 175 interaction with APOE status, manifest only beyond at least moderate AD-related neuropathology (e.g. amyloid or tau)¹⁴. The null AD case/control interaction could reflect that 176 177 UK Biobank is relatively healthy and well-educated. It is possible the UK Biobank 178 participants were not sufficiently old; analysis of longitudinal cognitive and brain imaging 179 data (in independent data) is indicative of more pronounced KL heterozygosity effects particularly into later life¹⁵. 180

181

182 Limitations

183 This study did not explore an exhaustive list of structural imaging phenotypes. There is some 184 degree of healthy volunteer bias in UK Biobank participants, and probably more so in 185 participants who returned for imaging. Some imaging participants would have been unable to 186 complete scanning due to contraindications related to poorer health, e.g. 187 pacemakers/stents¹¹.

188

189 <u>Summary</u>

A recent relatively large-scale study including cohort, case/control longitudinal and amyloidbeta data showed a significant interaction whereby KL genotype modified the well-known *APOE* e4 and dementia association. Using independent cognitive, structural brain and dementia data, we did not support these prior findings; this could reflect some degree of bias or imprecision in UK Biobank participants or phenotypes, or that the interaction while 'true' is contingent on AD-related neuropathology: future studies should investigate this further in deeply-phenotyped cohorts.

197 Funding

198 RT is funded by a Baillie Gifford doctoral student fellowship.UK Biobank was established by 199 the Wellcome Trust medical charity, Medical Research Council, Department of Health, 200 Scottish Government and the Northwest Regional Development Agency. It has also had 201 funding from the Welsh Assembly Government and the British Heart Foundation. DJS is 202 supported by an MRC Pathfinder grant.

203

204 Role of the funder/sponsor

- 205 The funders had no role in study design, data collection or management, analyses or
- 206 interpretation of the data, nor preparation, review or approval of the manuscript.

207

208 Conflict of interest disclosures

- 209 None.
- 210

211 Author contributions

- 212 Concept and design: DML
- 213 Acquisition, analysis, or interpretation of data: DML, RT.
- 214 Drafting of the manuscript: DML, RT.
- 215 Critical revision of the manuscript for important intellectual content: All co-authors.
- 216 Statistical analysis: DML.
- 217 Obtained principal study funding: DML, KF.

218 References

- Crenshaw DG, Gottschalk WK, Lutz MW, et al. Using Genetics to Enable Studies on
 the Prevention of Alzheimer's Disease. *Clin Pharmacol Ther.* 2013;93(2):177-185.
 doi:10.1038/clpt.2012.222
- Vo HT, Laszczyk AM, King GD. Klotho, the Key to Healthy Brain Aging? *Brain Plast*.
 Published online 2018. doi:10.3233/bpl-170057
- Belloy ME, Napolioni V, Han SS, Le Guen Y, Greicius MD. Association of Klotho-VS
 Heterozygosity with Risk of Alzheimer Disease in Individuals Who Carry APOE4.
 JAMA Neurol. Published online 2020. doi:10.1001/jamaneurol.2020.0414
- Bycroft C, Freeman C, Petkova D, et al. The UK Biobank resource with deep
 phenotyping and genomic data. *Nature*. Published online 2018. doi:10.1038/s41586 018-0579-z
- Lyall DM, Celis-Morales C, Lyall LM, et al. Assessing for interaction between APOE
 ε4, sex, and lifestyle on cognitive abilities. *Neurology*. Published online 2019.
 doi:10.1212/WNL.00000000007551
- Lyall DM, Cox SR, Lyall LM, et al. Association between APOE e4 and white matter
 hyperintensity volume, but not total brain volume or white matter integrity. *Brain Imaging Behav.* Published online 2019. doi:10.1007/s11682-019-00069-9
- Ferguson AC, Tank R, Lyall LM, et al. Alzheimer's Disease Susceptibility Gene
 Apolipoprotein E (APOE) and Blood Biomarkers in UK Biobank (N = 395,769). J
 Alzheimer's Dis. 2020;76(4):1541-1551. doi:10.3233/jad-200338
- Sudlow C, Gallacher J, Allen N, et al. UK Biobank: An Open Access Resource for
 Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age.
 PLoS Med. 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
- 242 9. Wilkinson T, Schnier C, Bush K, et al. Identifying dementia outcomes in UK Biobank:

a validation study of primary care, hospital admissions and mortality data. *Eur J Epidemiol.* 2019;34(6):557-565. doi:10.1007/s10654-019-00499-1

- Alfaro-Almagro F, Jenkinson M, Bangerter NK, et al. Image processing and Quality
 Control for the first 10,000 brain imaging datasets from UK Biobank. *Neuroimage*.
 Published online October 24, 2017. doi:10.1016/j.neuroimage.2017.10.034
- Ferguson AC, Tank R, Lyall LM, et al. Association of systolic blood pressure and body
 mass index with cognitive and structural brain phenotypes in UK Biobank. J
 Hypertens. Published online June 9, 2020. doi: 10.1097/HJH.00000000002579
- Lyall DM, Cullen B, Allerhand M, et al. Cognitive test scores in UK biobank: Data
 reduction in 480,416 participants and longitudinal stability in 20,346 participants.
 PLoS One. 2016;11(4). doi:10.1371/journal.pone.0154222
- Mengel-From J, Soerensen M, Nygaard M, McGue M, Christensen K, Christiansen L.
 Genetic variants in KLOTHO associate with cognitive function in the oldest old group.
 Journals Gerontol Ser A Biol Sci Med Sci. Published online 2016.
 doi:10.1093/gerona/glv163
- Neitzel J, Franzmeier N, Rubinski A, et al. KL-VS heterozygosity is associated with 258 14. 259 reduced tau accumulation and lower memory impairment in Alzheimer's disease KL-260 VS heterozygosity attenuates downstream effects of amyloid on tau and cognition. 261 medRxiv. Published online July 31, 2020:2020.07.29.20164434. 262 doi:10.1101/2020.07.29.20164434
- de Vries CF, Staff RT, Harris SE, et al. Klotho, APOEε4, cognitive ability, brain size,
 atrophy, and survival: a study in the Aberdeen Birth Cohort of 1936. *Neurobiol Aging*.
 Published online 2017. doi:10.1016/j.neurobiolaging.2017.02.019